When a company such as AlloVir conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ALVR split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AlloVir shares, starting with a $10,000 purchase of ALVR, presented on a split-history-adjusted basis factoring in the complete ALVR split history.

About AlloVir

AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus. According to our ALVR split history records, AlloVir has had 1 split.

ALVR Split History | www.SplitHistory.com | Copyright © 2013 - 2024, All Rights Reserved